Log In
BCIQ
Print this Print this
 

DMT210, SIG990

  Manage Alerts
Collapse Summary General Information
Company Signum Dermalogix Inc.
DescriptionTopical anti-inflammatory small molecule analog of isoprenylcysteine that inhibits toll-like receptor (TLR) and GPCR signaling
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationRosacea
Indication DetailsTreat moderate to severe rosacea
Regulatory Designation
PartnerDermata Therapeutics LLC

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/25/2015

Undisclosed

0

Undisclosed

04/23/2012

Undisclosed

0

Undisclosed

Get a free BioCentury trial today